freeze-thaw cycle comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
=== African-American communities === The war on drugs has incarcerated high numbers of African-Americans. However, the damage has compounded beyond individuals to affect African-American communities as a whole, with some social scientists suggesting the war on drugs could not be maintained without societal racism and the manipulation of racial stereotypes. African-American children are overrepresented in juvenile hall and family court cases, a trend that began during the war on drugs. From 1985 to 1999, admissions of blacks under the age of 18 increased by 68%. Some authors posit that the overrepresentation is caused by minority juveniles committing crime more often and more serious crimes. A compounding factor is often the imprisonment of a father. Boys with imprisoned fathers are significantly less likely to develop the skills necessary for success in early education. In addition, African-American youth often turn to gangs to generate income for their families, oftentimes more effectively than at a minimum wage or entry-level job. Still, this occurs even as substance abuse, especially marijuana, has largely declined among high school students. In contrast, many black youths drop out of school, are subsequently tried for drug-related crime, and acquire AIDS at disparate levels. In addition, the high incarceration rate has led to the juvenile justice system and family courts to use race as a negative heuristic in trials, leading to a reinforcing effect.
== Fourth Ministry == On 28 July 2005, following the resignation of Deputy Premier Terry Mackenroth from the ministry and from Parliament, a ministry of 19 cabinet ministers and 6 parliamentary secretaries was sworn in. It served until the reconstitution of the Ministry on 23 September 2006 following the 2006 election. Following a Crime and Misconduct Commission report on 7 December 2005, Gordon Nuttall resigned as a minister. Tim Mulherin was appointed in his place on 12 December.
=== Physiology === Nickel allergy results in a skin response after the skin comes in contact with an item that releases a large amount of nickel from its surface. It is commonly associated with nickel-containing belt buckles coming into prolonged contact with the skin. The skin reaction can occur at the site of contact, or sometimes spread beyond to the rest of the body. Free (released) nickel that is able to penetrate the skin is taken up by scavenger (dendritic) cells and then presented to the immune system T-Cells. With each subsequent exposure to nickel these T cells become stimulated and duplicate themselves. With enough exposure to nickel, the amassing clones of T-cells reach "threshold" and the skin develops a rash. The rash can appear as acute, subacute, or chronic eczema-like skin patches, primarily at the site of contact with the nickel (e.g., earlobe from nickel earrings). From the time of exposure, the rash usually appears within 12–120 hours and can last for 3–4 weeks or for the continued duration of nickel contact/exposure. Three simultaneous conditions must occur to trigger Ni-ACD:
Obstructive sleep apnea (OSA) is the most common sleep-related breathing disorder. This type of sleep apnea is characterized by recurrent episodes of complete or partial obstruction of the upper airway leading to reduced or absent breathing during sleep. These episodes are termed "apneas" with complete or near-complete cessation of breathing, or "hypopneas" when the reduction in breathing is partial. In either case, a fall in blood oxygen saturation, a sleep disruption, or both, may result. A high frequency of apneas or hypopneas during sleep may interfere with the quality of sleep, which – in combination with disturbances in blood oxygenation – is thought to contribute to negative consequences to health and quality of life. The terms obstructive sleep apnea syndrome (OSAS) or obstructive sleep apnea–hypopnea syndrome (OSAHS) may be used to refer to OSA when it is associated with symptoms during the daytime (e.g. excessive daytime sleepiness, decreased cognitive function). Most individuals with obstructive sleep apnea are unaware of disturbances in breathing while sleeping, even after waking up. A bed partner or family member may observe a person snoring or appear to stop breathing, gasp, or choke while sleeping. People who live or sleep alone are often unaware of the condition. Symptoms may persist for years or even decades without identification. During that time, the person may become conditioned to the daytime sleepiness, headaches, and fatigue associated with significant levels of sleep disturbance.
Sources: en.wikipedia.org
12 November – Downing Street confirms that Sue Gray will not take up a role as the prime minister's envoy to the nations and regions. The government sends a contingency of 470 delegates to the COP29 climate summit in Azerbaijan, with an estimated carbon dioxide footprint of at least 338 tons. The delegation is reported to comprise 354 government officials or ministers and 116 others including representatives from British overseas territories and crown dependencies, journalists, business figures and policy experts. By comparison, Italy sends 437, the US 405 and France 115. Starmer tells the COP29 climate conference that the UK will aim to reduce its emissions by 8% by 2035. Stephen Flynn, the SNP's leader at Westminster, announces his intention to stand at the 2026 Scottish Parliament election. Former Welsh government legal advisor Mick Antoniw and ex-minister Julie Morgan tell BBC News that subject to being passed at Westminster, the Terminally Ill Adults (End of Life) Bill would require a vote in the Senedd to become legal in Wales. 13 November – Health Secretary Wes Streeting orders a review into the potential cost to the NHS of implementing changes to the law regarding assisted dying. A report published by the Electoral Commission reveals that over half the 2024 general election candidates faced some kind of abuse. 14 November – Chancellor Rachel Reeves is reported to be planning the "biggest pension reform in decades" by merging council pension schemes into "pension megafunds" hoping they will boost economic growth.
====== Integration of 21st Century Fox characters ====== In December 2017, Disney agreed to acquire assets from 21st Century Fox, and finalized the transaction in March 2019. This saw the return of the film rights for the X-Men, Deadpool, and the Fantastic Four to Marvel Studios. Despite this, Feige said they could not yet immediately integrate these characters and concepts into the MCU because of corporate acquisition laws. Some of the first elements to be integrated into the MCU following the acquisition were the organization S.W.O.R.D. in the Disney+ series WandaVision (2021) and the fictional country Madripoor in the series The Falcon and the Winter Soldier (2021). More elements were integrated throughout the Multiverse Saga, including Patrick Stewart appearing as an alternate version of Charles Xavier, his role in Fox's X-Men film series, in the film Doctor Strange in the Multiverse of Madness (2022); "No Normal", the series finale of the miniseries Ms. Marvel (2022), revealing that Kamala Khan has a genetic mutation, with star Iman Vellani confirming that Kamala is the first mutant in the MCU; and Kelsey Grammer playing a version of his X-Men film series character Hank McCoy / Beast in the film The Marvels (2023).
== Oxygen-14 == Oxygen-14 (half-life 70.62 seconds) is the second most stable radioisotope of oxygen, and decays by positron emission to nitrogen-14. Oxygen-14 ion beams are of interest to researchers of proton-rich nuclei; for example, one early experiment at the Facility for Rare Isotope Beams in East Lansing, Michigan, produced a 14O beam by proton bombardment of 14N, using it to determine the absolute strength of the electron capture transition.
== Function == Glucagon-like peptide-1 (GLP-1) is a hormone consisting of 30 amino acids. GLP-1 is released by intestinal L cells when nutrients are consumed. GLP1R is expressed on beta cells in the pancreas. Binding of GLP-1 to GLP1R has multiple effects, including enhancing insulin secretion from pancreatic beta cells in response to glucose, increasing insulin expression, preventing beta-cell apoptosis, promoting the formation of new beta cells, reducing glucagon secretion, slowing down stomach emptying, promoting satiety, and improving glucose disposal in peripheral tissues. GLP1R is also expressed in the brain where it is involved in the control of appetite.
Fold Type I — aspartate aminotransferase family Fold Type II — tryptophan synthase family Fold Type III — alanine racemase family (TIM-barrel) Fold Type IV — D-amino acid aminotransferase family Fold Type V — glycogen phosphorylase family
Sources: en.wikipedia.org
=== Concept === Many airports had terminals too small for "aerobuses". In the West, the solution to this involved constructing greater airport capacity. By contrast, Soviet aviation research institutes addressed ways of increasing passenger throughput without the need for additional airport capacity. Many Soviet airports also had surfaces too weak for "aerobuses". The Soviet solution again favoured adapting aircraft to existing conditions, rather than reconstructing airports. The aerobus thus had to match the ground loadings of existing airliners. This called for complex multi-wheel landing gear. The Soviet solution to the airport capacity issue involved passengers loading and unloading their own luggage into and from the aircraft. This was eventually called "the luggage at hand system" (Russian: "система «багаж с собой»"; transliterated: "sistyema bagazh s soboy"). Soviet aviation journalist Kim Bakshmi described it (at its ultimate) thus: "One arrives five minutes prior to departure, buys oneself a ticket on board the aircraft, hangs one's coat next to the seat and places one's bag or suitcase nearby." Taking suitcases into the cabin, as in trains, was studied, but necessitated a 3 m fuselage extension with a 350-seat capacity. To avoid this, passengers were to deposit their luggage in underfloor compartments as they entered the airliner. Ideas similar to the "luggage at hand system" were briefly addressed in the West. Airbus studied such an arrangement in the mid-1970s.
In 2021 a 5Å CryoEM analysis revealed the relationship between the catalytic domains and the intact TPR regions confirming the dimer arrangement first seen in the TPR alone X ray structure. This structure supports an ordered sequential bi-bi mechanism that matches the fact that “at saturating peptide concentrations, a competitive inhibition pattern was obtained for UDP with respect to UDP-GlcNAc.”
==== Quantification ==== Polyphenolic content in vitro can be quantified by volumetric titration. An oxidizing agent, permanganate, is used to oxidize known concentrations of a standard tannin solution, producing a standard curve. The tannin content of the unknown is then expressed as equivalents of the appropriate hydrolyzable or condensed tannin. Some methods for quantification of total polyphenol content in vitro are based on colorimetric measurements. Some tests are relatively specific to polyphenols (for instance the Porter's assay). Total phenols (or antioxidant effect) can be measured using the Folin–Ciocalteu reaction. Results are typically expressed as gallic acid equivalents. Polyphenols are seldom evaluated by antibody technologies. Other tests measure the antioxidant capacity of a fraction. Some make use of the ABTS radical cation which is reactive towards most antioxidants including phenolics, thiols and vitamin C. During this reaction, the blue ABTS radical cation is converted back to its colorless neutral form. The reaction may be monitored spectrophotometrically. This assay is often referred to as the Trolox equivalent antioxidant capacity (TEAC) assay. The reactivity of the various antioxidants tested are compared to that of Trolox, which is a vitamin E analog. Other antioxidant capacity assays which use Trolox as a standard include the diphenylpicrylhydrazyl (DPPH), oxygen radical absorbance capacity (ORAC), ferric reducing ability of plasma (FRAP) assays or inhibition of copper-catalyzed in vitro human low-density lipoprotein oxidation.
One person was killed in a Russian attack in Kherson. Ukraine established a national registry to document sexual violence by Russian forces in the country. North Korean dictator Kim Jong Un pledged to “unconditionally support” Russia with its invasion of Ukraine during a visit by Putin to Pyongyang. Russian opposition media claimed that, during 2024, Russian aircraft accidentally dropped 103 bombs on Russian soil and Russian occupied territories.
The National Dope Testing Laboratory (NDTL) is a premier analytical testing & research organization established as an autonomous body under the Ministry of Youth Affairs and Sports, Government of India. It is the only laboratory in the country responsible for human sports dope testing. It is headed by Chief Executive Officer (CEO). Dr. Puran Lal Sahu is the Scientific Director of NDTL. It is accredited by National Accreditation Board for Testing & Calibration Laboratories, NABL (ISO/IEC 17025:2017) for human dope testing of urine & blood samples from human sports. NDTL is one of the 29 WADA accredited laboratories Archived 2021-04-18 at the Wayback Machine in the world. It is one of the modern and state-of-the-art laboratories in the country equipped with the latest analytical instrumentation.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.